Vaxcell-Bio Therapeutics Co. Ltd

KQ:323990 Korea Biotechnology

Market Cap

$131.21 Million

₩192.11 Billion KRW

Market Cap Rank

#18102 Global

#650 in Korea

Share Price

₩8290.00

Change (1 day)

+2.35%

52-Week Range

₩7400.00 - ₩11000.00

All Time High

₩203065.93

Vaxcell-Bio Therapeutics Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 32.97%

Vaxcell-Bio Therapeutics Co. Ltd (323990) has an Asset Resilience Ratio of 32.97% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩23.24 Billion

Cash + Short-term Investments

Total Assets

₩70.50 Billion

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Vaxcell-Bio Therapeutics Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Vaxcell-Bio Therapeutics Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩23.24 Billion	32.97%
Total Liquid Assets	₩23.24 Billion	32.97%

Asset Resilience Insights

Very High Liquidity: Vaxcell-Bio Therapeutics Co. Ltd maintains exceptional liquid asset reserves at 32.97% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.